FeraMAX(MD) Pd Thérapeutique 150
Biosyent annonce le lancement du nouveau FeraMAX(MD) Pd Thérapeutique 150
November 05, 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, 05 nov. 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », « la Société », Bourse de croissance : RX) a le plaisir d’annoncer le lancement de FeraMAXMD Pd Thérapeutique 150,...
BioSyent logo.png
BioSyent Named to the Growth List Ranking of Canada’s Fastest-Growing Companies for Eighth Consecutive Year
October 15, 2020 09:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Oct. 15, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been included in the 32nd annual Growth List, the definitive...
BioSyent logo.png
BioSyent Annonce L'Introduction du Nouveau FeraMAX® Pd
October 05, 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, 05 oct. 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », « la Société », Bourse de croissance : RX) a le plaisir d’annoncer l’introduction de FeraMAX® Pd, une nouvelle...
BioSyent logo.png
BioSyent Announces Introduction of New FeraMAX® Pd
October 05, 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Oct. 05, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the introduction of FeraMAX® Pd, a new oral iron supplement...
BioSyent logo.png
BioSyent Signs Exclusive Agreement for New Women’s Health Product
October 01, 2020 09:25 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Oct. 01, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive License...
BioSyent logo.png
BioSyent Releases Q2 and H1 2020 Results
August 26, 2020 07:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 26, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30,...
BioSyent logo.png
BioSyent to Present at the LD 500 Virtual Conference
August 24, 2020 16:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 24, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today announced that it will be presenting at the LD 500 investor conference on...
BioSyent logo.png
BioSyent Schedules Q2 and H1 2020 Earnings Release for August 26, 2020
August 17, 2020 08:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 17, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30,...
BioSyent logo.png
BioSyent Announces the Availability of Tibella® (tibolone) in Canada
July 29, 2020 16:01 ET | BioSyent Inc.
MISSISSAUGA, Ontario, July 29, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today announced the Canadian launch and product availability of Tibella® (tibolone)...
BioSyent logo.png
BioSyent Releases Results for Q1 2020
May 28, 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 28, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three months ended March 31, 2020. Key...